Tarsus Pharmaceuticals, Inc. (TARS) Research

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.

Market snapshot

Symbol
TARS
Price
$63.16
Day change
+0.98%
Market cap
$2.7B
P/E ratio
-56.21x
52-week range
38.51-85.25
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$68.00

Peer companies

  • Ascentage Pharma Group International (AAPG)
  • Adaptive Biotechnologies Corporation (ADPT)
  • Arcutis Biotherapeutics, Inc. (ARQT)
  • Celcuity Inc. (CELC)
  • CG Oncology, Inc. Common stock (CGON)
  • Disc Medicine, Inc. (IRON)
  • Legend Biotech Corporation (LEGN)
  • Scholar Rock Holding Corporation (SRRK)

Recent insider activity

  • Farrow Jeffrey S — M-Exempt (27881 shares) on 2026-06-15
  • Farrow Jeffrey S — S-Sale (14396 shares) on 2026-06-16
  • Farrow Jeffrey S — M-Exempt (27881 shares) on 2026-06-15
  • Goodrich Katherine — S-Sale (2954 shares) on 2026-06-15
  • LINK WILLIAM J PHD — S-Sale (10572 shares) on 2026-06-15

Open Tarsus Pharmaceuticals, Inc. (TARS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.